Andrew James Chapman, DPM in Big Stone Gap, VA - Medicare Podiatry Provider

Andrew James Chapman, DPM is a medicare enrolled "Podiatrist - Foot & Ankle Surgery" provider in Big Stone Gap, Virginia. He went to Emory University School Of Medicine and graduated in 1986 and has 38 years of diverse experience with area of expertise as Podiatry. His current practice location is 2537 4th Ave E, Big Stone Gap, Virginia. You can reach out to his office (for appointments etc.) via phone at (276) 523-3696.

Andrew James Chapman is licensed to practice in Virginia (license number 0103000781) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1760596829.

Contact Information

	Andrew James Chapman, DPM
	2537 4th Ave E, Big Stone Gap, VA 24219-3601
	(276) 523-3696
	(276) 523-4806

Healthcare Provider's Profile

Full Name	Andrew James Chapman
Gender	Male
Speciality	Podiatry
Experience	38 Years
Location	2537 4th Ave E, Big Stone Gap, Virginia
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Andrew James Chapman attended and graduated from Emory University School Of Medicine in 1986

NPI Data:

NPI Number: 1760596829
Provider Enumeration Date: 08/18/2006
Last Update Date: 01/22/2008

Medicare PECOS Information:

PECOS PAC ID: 9335274893
Enrollment ID: I20100323000337

Medical Identifiers

Medical identifiers for Andrew James Chapman such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1760596829	NPI	-	NPPES
1391888	Other	VA	UMWA
244155	Other	VA	BCBS
9300121	Medicaid	VA

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
213ES0103X	Podiatrist - Foot & Ankle Surgery	0103000781 (Virginia)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Andrew James Chapman is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Andrew James Chapman, DPM Po Box 328, Big Stone Gap, VA 24219-0328 Ph: (276) 523-3696	Andrew James Chapman, DPM 2537 4th Ave E, Big Stone Gap, VA 24219-3601 Ph: (276) 523-3696

News Archive

Breakthrough study opens door to design of whitening compounds for removing skin discolorations

Spots resulting from too much sun exposure and other effects of dysfunctional melanin production may become a thing of the past.

Study reports case-specific monetary estimates for childhood illness linked to air pollution

A new study by researchers at the Columbia Center for Children's Environmental Health (CCCEH) at Columbia Mailman School of Public Health is the first to compile the estimated per-case costs of six childhood health conditions linked to air pollution-estimates that can be incorporated into benefits assessments of air pollution regulations and climate change mitigation policies.

Study confirms safety of LINX Reflux Management System for GERD treatment

Millions of Americans suffer from Gastroesophageal Reflux Disease (GERD), a chronic, often progressive disease that can cause debilitating symptoms and lead to serious complications including pre-cancerous Barrett's esophagus and esophageal cancer.

LSTM receives grant to help improve health of people living in informal settlements

The Liverpool School of Tropical Medicine has been awarded £11.8 million by the UK government's Global Challenges Research Fund for a grant to help improve the health of people living in informal settlements in low and middle-income countries.

Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development

SuppreMol GmbH, an autoimmune disease specialist, today announced a licensing agreement with the University Hospital of Regensburg to develop SM401, a humanized anti-IL-3 monoclonal antibody for early diagnosis and treatment of Rheumatoid Arthritis (RA). SuppreMol will advance preclinical development of SM401 for treatment of RA. Simultaneously, the Company will further validate a highly sensitive human IL-3 diagnostic assay for patient stratification.

Andrew James Chapman, DPM - Medicare Podiatrist in Big Stone Gap, VA